If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

PSE - Awards Finalist

5 Jun 2007 11:03

Imperial Innovations Group plc05 June 2007 5 June 2007 Imperial Innovations Group plc ("Imperial Innovations") PSE Finalist for MacRobert Award Imperial Innovations Group plc (AIM: IVO), the technology commercialisation andinvestment company, announces that an Imperial Innovations spin-out company,Process Systems Enterprise (PSE), was today revealed to be one of the fourfinalists for the Royal Academy of Engineering's MacRobert Award. The award, theUK's most prestigious for engineering, recognises the successful development ofinnovative ideas in engineering. The winning company is honoured with a goldmedal and the winning team members receive a prize of £50,000. Process Systems Enterprise was selected for its innovative gPROMS(R) advancedprocess modelling software. gPROMS helps process industry companies to maximiseproduct quality, minimise production cost and control environmental impactthrough the use of high-accuracy predictive mathematical models of theirprocesses. It also enables them to innovate much faster, design more efficientprocesses, manage risk closely and integrate R&D and engineering disciplines. gPROMS has successfully entered the worldwide market, with 75% of PSE's revenuescoming from exports. The company's client base includes more than 60 of theworld's leading process industry companies, about 75% of which are Fortune 500organisations. gPROMS is also being used for teaching and research by more than200 universities worldwide. The company was formed in 1997 by Imperial Innovations and is based ontechnology arising from the research of Professor Costas Pantelides andcolleagues from the Centre for Process Systems Engineering at Imperial CollegeLondon. Prof. Costas Pantelides, MD of PSE, says "The process industry is going througha period of significant opportunities and challenges: unprecedented demand forproducts, increasing customer expectations of product performance, decreasingavailability of primary raw materials, and global concerns relating to energyconsumption, safety and environmental impact. We bring the means to make sounddecisions while minimising the risk inherent in innovation". Susan Searle, CEO of Imperial Innovations said, "Imperial Innovations isdelighted that PSE is being considered for the MacRobert awards. We recognisethe tremendous progress and future potential of PSE, and are working with thecompany closely to develop new geographical markets and sectors for its growth.In particular, we see that PSE has major potential in the environment sectorwhere companies are designing new product manufacturing methods with lowercarbon footprints and large metropolitan areas are developing moreenvironmentally sustainable urban systems. We are helping PSE find new channelpartners to accelerate its growth and realise its full potential." -Ends- For more information contact: Imperial InnovationsSusan Searle, Chief Executive Officer +44 (0)20 7594 6591Lucy Ahfong, Marketing Communications Executive +44 (0)20 7594 6644 M:CommunicationsHarriet Totty / Eleanor Williamson +44 (0)20 7153 1539 JP Morgan Cazenove +44 (0)20 7588 2828Steve Baldwin Notes to Editors About Imperial InnovationsImperial Innovations is one of the UK's leading technology transfer andcommercialisation companies. The company was founded in 1986 and its ordinaryshares admitted to trading on the AIM Market of London Stock Exchange plc inJuly 2006, raising £26 million. The company's integrated approach encompassesthe identification of ideas, protection of intellectual property, developmentand licensing of technology and formation, incubation and investment intechnology businesses. A wide range of technologies are commercialised withinthe areas of healthcare, energy, environment and emerging technology trends. Based at Imperial College London, the company has established equity holdings in70 technology businesses and has completed 116 commercial agreements. ImperialInnovations also commercialises technologies originating from outside ImperialCollege through incubation contracts with the Carbon Trust and WRAP and hasrelationships with a number of multinational corporations including BAE Systems. Imperial Innovations has invested in a range of spin-out companies, includingThe Acrobot Company Limited, BioCeramic Therapeutics Limited, Cardiak Limited,Circassia Holdings Limited, deltaDOT Limited, Equinox Pharma Limited, FutureWaves PTE Limited, HeliSwirl Technologies Limited, InforSense Limited, IXICOLimited, Lontra Limited, Midaz Lasers Limited, NanoBioDesign Limited, NexeonLimited, NovaThera Limited, Thiakis Limited and Veryan Medical Limited. Imperial Innovations currently holds shares in four technology businesses nowlisted on AIM including the fuel cell company, Ceres Power plc. www.imperialinnovations.co.uk About Process Systems Enterprise Ltd PSE (www.psenterprise.com) is one of the world's foremost providers of AdvancedProcess Modelling software and Model-Based Innovation services to the processmanufacturing industries. These apply high-accuracy mathematical models ofprocess equipment and phenomena to provide high-quality information for decisionsupport in process innovation, design and operation. Use of PSE's technology and services results in faster innovation, improveddesigns of processes and products, enhancement of existing operations and moreeffective R&D and experimental programmes. Results are achieved with relativelylow investment compared to alternative approaches - where these exist - withrapid return on investment and transfer of modelling know-how to industry. PSE's global customer base of process manufacturing companies and theirtechnology suppliers is served by offices in the UK, USA, Germany and Japan, andagencies in China, India and Korea. About gPROMS gPROMS(R) is the world's leading Advanced Process Modelling (APM) environment.It is used to provide high-quality information for decision support ininnovation, design and operation across all sectors of the process industries,with particular focus on modelling of complex operations such as reaction,crystallisation and polymerisation. Companies apply gPROMS to reduce time-to-market for new processes or products,improve designs, enhance production, reduce capital and operating expenditureand comply more effectively with safety, health and environmental requirements. gPROMS is applied across the 'process lifecycle', from laboratoryexperimentation, through process and detailed design, to online operation, andis central to the emerging technology of Model-Based Innovation. PSE iscommitted to maintaining gPROMS at the leading edge of modelling technology. http://www.psenterprise.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
30th May 20147:00 amRNSVeryan announces results on two-year Mimics study
22nd May 20147:00 amRNSYoyo closes £2.8 million seed investment round
6th May 20142:45 pmRNSHolding(s) in Company
24th Apr 20147:00 amRNSNexeon completes manufacturing facility
14th Apr 201412:00 pmRNSDirector change
3rd Apr 20143:36 pmRNSDirector's share purchase
28th Mar 20147:01 amRNSHalf Yearly Report
13th Mar 20141:04 pmRNSNotice of Results
13th Mar 20147:01 amRNSCircassia announces offer price
26th Feb 20147:40 amRNSCircassia indicative pricing notification
6th Feb 20147:03 amRNSCircassia announces intention to float
28th Jan 20147:00 amRNSAppointment of Joint Broker
7th Jan 20147:00 amRNSCell Medica achieves EU orphan drug designation
30th Dec 201310:00 amRNSFurther investment in TopiVert
18th Dec 20137:00 amRNS£5.1m funding round for Econic Technologies
17th Dec 201312:32 pmRNSResult of AGM
17th Dec 20139:00 amRNS£17.5m funding round for Crescendo Biologics
11th Dec 20137:00 amRNSIXICO launches first CE marked device
10th Dec 20137:00 amRNSSeed funding round for Cambridge spinout Aqdot
6th Dec 20137:00 amRNSGrant of share options
22nd Nov 20133:24 pmRNSOxford Immunotec trading commences on NASDAQ
20th Nov 20139:25 amRNSPulmocide receives £17m Series A funding
18th Nov 20137:00 amRNSMISSION Therapeutics receives £20m funding
16th Oct 20137:01 amRNSOxford Immunotec makes public S1 for potential IPO
16th Oct 20137:00 amRNSBoard Changes
16th Oct 20137:00 amRNSFinal Results
1st Oct 20139:00 amRNSCircassia grass allergy treatment success
26th Sep 20137:00 amRNSCell Medica opens commercial facility in Germany
23rd Sep 20137:05 amRNSIXICO expands into digital healthcare
23rd Sep 20137:00 amRNSProposed acquisition of IXICO Limited
20th Sep 20139:00 amRNSNotice of Results
12th Sep 20137:00 amRNSCircassia phase II clinical study success
10th Sep 20137:00 amRNSLeads £8m funding round in Plaxica
29th Aug 20137:00 amRNSInvestment in new mobile payments business
12th Aug 20136:01 pmRNSDirector/PDMR Shareholding
26th Jul 20138:45 amRNSPortfolio company PolyTherics merges with Antitope
17th Jul 20137:00 amRNSDirectorate Change
2nd Jul 20137:00 amRNS£30m loan from EIB for healthcare investment
25th Jun 20137:00 amRNSInvestment in PsychologyOnline
4th Jun 20137:00 amRNSAutifony starts phase I trial
8th May 20137:00 amRNSCell Medica treats first patient in new trial
29th Apr 20137:00 amRNSInvestment team appointment
17th Apr 20139:26 amRNSBoard change
22nd Mar 20137:00 amRNSHalf year results
1st Mar 20139:22 amRNSNotice of Results
1st Mar 20138:38 amRNSNotification of major interest in shares
25th Feb 20137:00 amRNSCircassia's cat allergy treatment
14th Feb 20137:00 amRNSInvestment in new technology company
23rd Jan 20137:00 amRNS£1.5m investment in new software portfolio company
21st Jan 20133:45 pmRNSListing of shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.